[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485179":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":52,"id":76,"slug":10,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":10,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":10,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Wuxi Hisky Medical Technology Co Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who diagnosed as T2DM",null,"Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes",[13],"Procedure: Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination","Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination",[9],[21],{"name":22,"affiliation":23,"role":24},"Ling Li, Professor","Zhongda Hospital","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+8613951606816","lingli2022@hotmail.com",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Weixia Sun","+8615562596360","weixia19960914@163.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Zhongda Hospital, Medical School, Southeast University","RECRUITING","Nanjing","Jiangsu","China","CN",{"type":43,"coordinates":44},"Point",[45,46],118.77778,32.06167,{"lat":46,"lon":45},[49],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[53,55,57,60,62,64,66,68,70,72,74],{"name":23,"class":54},"OTHER",{"name":56,"class":54},"Suzhou Municipal Hospital",{"name":58,"class":59},"Suzhou Fifth People's Hospital","UNKNOWN",{"name":61,"class":59},"Xuzhou Mining Group General Hospital",{"name":63,"class":54},"Nantong First People's Hospital",{"name":65,"class":59},"Changzhou Second People's Hospital",{"name":67,"class":59},"Huaian Second People's Hospital",{"name":69,"class":59},"Huaian Hospital",{"name":71,"class":59},"Taizhou Jiangyan Traditional Chinese Medicine Hospital",{"name":73,"class":59},"Yangzhou Jiangdu People's Hospital",{"name":75,"class":59},"Huaian Xuyi County People's Hospital","100485179",false,"NCT05597709","Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China","Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study","Inclusion Criteria:\n\n* Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes\n* UAP were measured based on iLivTouch\n* Willing to attend this study and able to provide the written informed consent.\n\nExclusion Criteria:\n\n* Other types of diabetes\n* Patients unable to receive regular follow-up","ALL","18 Years",{"count":85,"type":86},2900,"ESTIMATED","OBSERVATIONAL","In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.",[90,91],"Type 2 Diabetes Mellitus in Remission","Metabolic Associated Fatty Liver Disease",[93,94,95],"Type 2 diabetes mellitus","Metabolic associated fatty liver disease","ultrasound attenuation parameter","2022-10-24",{"date":98,"type":99},"2022-10-28","ACTUAL",{"date":101,"type":99},"2022-07-01",{"date":103,"type":86},"2027-06-01",{"name":5,"class":6},1]